Ticker: BIXT

BIOXYTRAN, Inc. (PINK: BIXT) Quick take: management is advancing R&D and clinical programs while running critically low on cash. The quarter produced a small GAAP profit driven by a favorable mark-to-market on an embedded derivative, but the balance sheet shows large liabilities, heavy potential...